[Therapeutic effect of anti-HMGB1 antibody and anti-RAGE antibody on SIRS/sepsis].

High mobility group box-1 (HMGB1) is intranuclear architectural protein. Once HMGB1 released to extracellular, it has been implicated to act as a novel proinflammatory cytokine, called "Late mediator", in SIRS/sepsis. This danger signal transmits through receptor for advanced glycation end-products (RAGE). In this study, we hypothesized whether treatment of anti-HMGB1 or anti-RAGE antibody would block LPS-lethality in septic mice. We measured survival rate of septic mice with or without antibodies, resulting in significant improvement with antibodies-treated mice. LPS-induced acute lung injury was almost disappeared by antibody treatment, because these antibodies were inhibited HMGB1 and RAGE expression in lung. Treatment of anti-HMGB1 or anti-RAGE antibody seems to be valid therapy against SIRS/sepsis.